CD96 and acute lymphoblastic leukemia: A potential target of interest is also the anti-CD96 mAb (TH-111) that has been shown to stain a major (78.3%) subset of T-ALL [37] with limited reactivity with blood and bone marrow cells, therefore representing a potential target.